Pfizer agrees to buy Global Blood Therapeutics in deal valued at $5.4 billion: WSJ
Blue Apron cuts 2022 revenue growth outlook to 7%-13% from 'mid-teens' percentage range
Blue Apron Q2 orders 1.70 mln vs. 1.98 mln a year ago, ave. order value $67.14 vs. $62.72
Blue Apron Q2 revenue $124.2 mln vs. $124.0 mln a year ago; FactSet consensus $124.9 mln
Blue Apron Q2 per-share loss 68 cents vs. loss 98 cents a year ago
First Solar upgraded to overweight from neutral at J.P. Morgan
Elevation Oncology downgraded to neutral from overweight at J.P. Morgan
Carvana downgraded to underweight from neutral at J.P. Morgan
Ball Corp. downgraded to neutral from overweight at J.P. Morgan
Lifetime Brands stock price target cut to $11.00 from $17.50 at D.A. Davidson
Redfin stock price target cut to $10.50 from $13.00 at Susquehanna
Canopy Growth stock price target cut to C$2 from C$5 at Benchmark
SoftBank Posts a Record Loss, Says Exploring a Sale of Fortress
Virtual Stock Exchange